UBS Group AG Has $6.56 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX

UBS Group AG trimmed its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 61.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 543,323 shares of the company’s stock after selling 861,148 shares during the period. UBS Group AG’s holdings in Amylyx Pharmaceuticals were worth $6,563,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of AMLX. Millennium Management LLC lifted its holdings in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after buying an additional 2,487,617 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Amylyx Pharmaceuticals by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock valued at $7,090,000 after buying an additional 143,065 shares during the period. JPMorgan Chase & Co. lifted its holdings in Amylyx Pharmaceuticals by 62.7% in the second quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company’s stock valued at $564,000 after buying an additional 33,920 shares during the period. Legal & General Group Plc acquired a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $47,000. Finally, Rhumbline Advisers acquired a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $645,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $12.74 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 52 week low of $4.64 and a 52 week high of $18.60. The company has a market capitalization of $1.42 billion, a PE ratio of -8.49 and a beta of -0.11. The company has a 50 day moving average price of $15.24 and a two-hundred day moving average price of $14.22.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AMLX. Bank of America increased their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 25th. Stifel Nicolaus began coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price objective on the stock. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Finally, Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.00.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.